From 3-D modeling to tamper-resistant drugs to personalized genomics, these companies put the "tech" in "biotech."
Three European panel recommendations, a clinical update for a lead drug candidate, and a biotech splitting into two companies, are the lead stories this week.
With nearly six dozen health-care companies reporting earnings this week, consider these five the most important.
Four positive clinical trials had investors jumping for joy in the biotech sector this week.
Arena Pharmaceuticals presses on as it waits to launch its obesity drug Belviq.
A "breakthrough therapy" designation, an accelerated new drug application go-ahead from the Food and Drug Administration, and plenty of analyst upgrades dominated the biotech scene this week.
Are these Wall Street upgrades really deserved?
Two drugmakers, and one drug retailer. These three health-care stocks experienced a humongous week.
Buffett generally shuns biotech, but one company in particular meets all the criteria he typically looks for, including sustainability, growth, and income.
The Motley Fool's exclusive bracket decides what health-care stock is the best investment